Cardiogen is a short peptide with known properties as a bioregulator. Research shows that its primary effects are on fibroblasts, the cells responsible for tissue repair and scar formation throughout the body. Though the focus on cardiogen has been on its role in a variety of cardiovascular diseases (hence the name), research shows that its ability to alter fibroblast activity has potential benefits in a variety of tissues. In addition, cardiogen appears to by a synergistic peptide, enhancing the benefit of certain standard therapies and thereby improving long-term outcomes while reducing side effects. Finally, preliminary research in rat models suggests that cardiogen may increase rates of apoptosis in tumor cells.
Molecular Formula: C18H31N7O9
Molecular Weight: 489.5 g/mol
PubChem CID: 11583989
Alternative Names: SCHEMBL3194515
In the heart, cardiogen appears to stimulate cardiomyocyte proliferation while reducing fibroblast growth and development. This leads to decreased scar formation and improved long-term outcomes in regards to cardiac remodeling leading to heart failure. Additionally, it appears that cardiogen 20mg can decrease p53 protein expression and thereby diminish rates of apoptosis[1].
Even though cardiogen reduces apoptosis in heart cells by down-regulating p53 expression, it may have the opposite effect in tumor cells. Research in rat models of M-1 sarcoma shows that apoptosis levels are higher in the tumor cells following cardiogen administration. What is more, the effect is does-dependent, indicating that the biological effect is real[2]. The peptide appears to enhance apoptosis in tumor cells and may be somewhat selective for tumor cells due to their enhanced and unusual vascular supply. This may make cardiogen a targeted treatment for at least some types of cancer. In addition, if the peptide enhances the action of standard cancer treatments (as it does in heart disease treatment), then it may prove a very potent addition to the arsenal of cancer fighters.
Doctors Levdik and Knyazkin, both of whom have worked in some capacity with Vladimir Khavinson through the St. Petersburg Institute of Bioregulation and Gerontology and the Russian Academy of Medical Sciences, have extensive experience researching the impact of amino acids and short peptides on both cancer and healthy tissues as they become dysfunctional and precancerous. Their work with Cardiogen 20mg has positioned it as the next possible candidate for approval, in Russia, for the treatment of sarcoma.
Research in tissue cultures shows that cardiogen, along with several similar peptides, alters the expression of signaling factors in fibroblasts of the prostate. Levels of these signaling factors are important in establishing favorable a microenvironment within tumors and may contribute to both the development and progression of prostate cancer. Solid evidence shows that the synthesis of these markers is substantially altered in aging and senescent fibroblasts, which may explain why prostate cancer is almost ubiquitous in older men but nearly unheard of in younger men[3]. In fact, studies show that cardiogen can normalize levels of these signaling molecules to match or even improve upon what is seen in young cell cultures, suggesting that cardiogen may be effective both in preventing prostate cancer and in controlling its progression once it develops[4].
Cardiogen 20mg, while less researched than some other bioregulators, appears to have potent effects on multiple body tissues including the heart and prostate. Additionally, the peptide may be beneficial in the treatment of certain types of cancer, particularly sarcoma. Currently, the biggest benefits of cardiogen appear to be in the settings of heart attack, hypertension, and chronic heart failure where the peptide not only offers benefits of its own accord, but acts in a synergistic manner with established treatments.
USD
EUR
GBP
CAD